Skip to main content

Jubilant's anti-infection drug receive US regulator nod

 

Clinical courses

Jubilant Life Sciences has announced that it had received approval of the US Food and Drug Administration (FDA) for its tablets used in treating adults for various infections, including pneumonia. The market size for Levofloxacin is estimated to be $28 million (Rs.179 crore) per annum.

The company said "Levofloxacin tablets are the generic version of Levaquin of Ortho-McNeil, used for treating infections such as pneumonia, sinusitis, bronchitis, prostatitis, urinary tract and inhalational anthrax,"

The company, which had 806 filings for formulations till March 31, 2015, got approval for 368 of them from various regions worldwide, including 72 from FDA. Jubilant manufactures and supplies active pharmaceutical ingredients, solid dosage formulations, specialty pharmaceuticals and life science ingredients.

The company also provides services in contract manufacturing and drug discovery solutions to global firms from its 10 production units in India, Canada and the US.


<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>